U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H15ClNO4.Na.3H2O
Molecular Weight 433.815
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of INDOMETHACIN SODIUM

SMILES

O.O.O.[Na+].COC1=CC2=C(C=C1)N(C(=O)C3=CC=C(Cl)C=C3)C(C)=C2CC([O-])=O

InChI

InChIKey=UHYAQBLOGVNWNT-UHFFFAOYSA-M
InChI=1S/C19H16ClNO4.Na.3H2O/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12;;;;/h3-9H,10H2,1-2H3,(H,22,23);;3*1H2/q;+1;;;/p-1

HIDE SMILES / InChI

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C19H16ClNO4
Molecular Weight 357.788
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://clinicaltrials.gov/ct2/show/NCT02183168 | https://clinicaltrials.gov/ct2/show/NCT02770950 | https://www.ncbi.nlm.nih.gov/pubmed/20503989 | https://www.ncbi.nlm.nih.gov/pubmed/14056924 | https://www.ncbi.nlm.nih.gov/pubmed/27988363

Indometacin (INN and BAN) or indomethacin (AAN, USAN, and former BAN) is a nonsteroidal anti-inflammatory drug (NSAID) commonly used as a prescription medication to reduce fever, pain, stiffness, and swelling from inflammation. Indomethacin has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of Indometacin, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Indomethacin is a potent inhibitor of prostaglandin synthesis in vitro. Indomethacin concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Because indomethacin is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues. Indometacin is indicated for: Moderate to severe rheumatoid arthritis including acute flares of chronic disease, Moderate to severe ankylosing spondylitis, Moderate to severe osteoarthritis, Acute painful shoulder (bursitis and/or tendinitis), Acute gouty arthritis. In general, adverse effects seen with indomethacin are similar to all other NSAIDs. For instance, indometacin inhibits both cyclooxygenase-1 and cyclooxygenase-2, it inhibits the production of prostaglandins in the stomach and intestines, which maintain the mucous lining of the gastrointestinal tract. Indometacin, therefore, like other non-selective COX inhibitors can cause peptic ulcers. These ulcers can result in serious bleeding and/or perforation requiring hospitalization of the patient. To reduce the possibility of peptic ulcers, indomethacin should be prescribed at the lowest dosage needed to achieve a therapeutic effect, usually between 50–200 mg/day. It should always be taken with food. Nearly all patients benefit from an ulcer protective drug (e.g. highly dosed antacids, ranitidine 150 mg at bedtime, or omeprazole 20 mg at bedtime). Other common gastrointestinal complaints, including dyspepsia, heartburn and mild diarrhea are less serious and rarely require discontinuation of indomethacin.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
INDOCIN

Approved Use

TIVORBEX is indicated for treatment of mild to moderate acute pain in adults. TIVORBEX is a NSAID indicated for treatment of mild to moderate acute pain in adults (1).

Launch Date

1965
Primary
INDOCIN

Approved Use

TIVORBEX is indicated for treatment of mild to moderate acute pain in adults. TIVORBEX is a NSAID indicated for treatment of mild to moderate acute pain in adults (1).

Launch Date

1965
Primary
INDOCIN

Approved Use

TIVORBEX is indicated for treatment of mild to moderate acute pain in adults. TIVORBEX is a NSAID indicated for treatment of mild to moderate acute pain in adults (1).

Launch Date

1965
Primary
INDOCIN

Approved Use

TIVORBEX is indicated for treatment of mild to moderate acute pain in adults. TIVORBEX is a NSAID indicated for treatment of mild to moderate acute pain in adults (1).

Launch Date

1965
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2369 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
INDOMETHACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
2 μg/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
INDOMETHACIN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
7762 ng × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
INDOMETHACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7.22 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
INDOMETHACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
INDOMETHACIN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.9 g single, oral
Overdose
Dose: 0.9 g
Route: oral
Route: single
Dose: 0.9 g
Sources: Page: p.152
unhealthy, 15
n = 1
Health Status: unhealthy
Condition: Knee pain
Age Group: 15
Sex: F
Population Size: 1
Sources: Page: p.152
Disc. AE: Vomiting, Nausea...
AEs leading to
discontinuation/dose reduction:
Vomiting
Nausea (mild)
Anorexia (mild)
Sources: Page: p.152
20 mg 3 times / day multiple, oral
Dose: 20 mg, 3 times / day
Route: oral
Route: multiple
Dose: 20 mg, 3 times / day
Sources:
unhealthy, adult
n = 91
Health Status: unhealthy
Condition: Acute Postoperative Pain
Age Group: adult
Sex: M+F
Population Size: 91
Sources:
Other AEs: Headache, Pruritus...
Other AEs:
Headache (below serious, 11 patient)
Pruritus (below serious, 5 patients)
Sources:
20 mg 3 times / day multiple, oral
Dose: 20 mg, 3 times / day
Route: oral
Route: multiple
Dose: 20 mg, 3 times / day
Sources:
unhealthy, adult
n = 92
Health Status: unhealthy
Condition: Acute Postoperative Pain
Age Group: adult
Sex: M+F
Population Size: 92
Sources:
Other AEs: Nausea, Vomiting...
Other AEs:
Nausea (below serious, 34 patients)
Vomiting (below serious, 11 patient)
Constipation (below serious, 8 patients)
Sources:
40 mg 2 times / day multiple, oral
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, adult
n = 91
Health Status: unhealthy
Condition: Acute Postoperative Pain
Age Group: adult
Sex: M+F
Population Size: 91
Sources:
Other AEs: Deep vein thrombosis, Headache...
Other AEs:
Deep vein thrombosis (serious, 1 patient)
Headache (below serious, 13 patients)
Pruritus (below serious, 1 patient)
Presyncope (below serious, 5 patients)
Sources:
40 mg 2 times / day multiple, oral
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, adult
n = 93
Health Status: unhealthy
Condition: Acute Postoperative Pain
Age Group: adult
Sex: M+F
Population Size: 93
Sources:
Other AEs: Nausea, Vomiting...
Other AEs:
Nausea (below serious, 36 patients)
Vomiting (below serious, 12 patients)
Constipation (below serious, 7 patients)
Post procedural haemorrhage (below serious, 7 patients)
Sources:
40 mg 3 times / day multiple, oral
Dose: 40 mg, 3 times / day
Route: oral
Route: multiple
Dose: 40 mg, 3 times / day
Sources:
unhealthy, adult
n = 93
Health Status: unhealthy
Condition: Acute Postoperative Pain
Age Group: adult
Sex: M+F
Population Size: 93
Sources:
Other AEs: Headache, Pruritus...
Other AEs:
Headache (below serious, 12 patients)
Pruritus (below serious, 3 patients)
Sources:
40 mg 3 times / day multiple, oral
Dose: 40 mg, 3 times / day
Route: oral
Route: multiple
Dose: 40 mg, 3 times / day
Sources:
unhealthy, adult
n = 94
Health Status: unhealthy
Condition: Acute Postoperative Pain
Age Group: adult
Sex: M+F
Population Size: 94
Sources:
Other AEs: Headache, Vomiting...
Other AEs:
Headache (below serious, 17 patients)
Vomiting (below serious, 9 patients)
Sources:
50 mg 3 times / day multiple, oral
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Bursitis|Tendinitis|Gouty arthritis
Sources:
Disc. AE: Cardiac thrombosis, Myocardial infarction...
AEs leading to
discontinuation/dose reduction:
Cardiac thrombosis (serious)
Myocardial infarction (grade 3-5)
Stroke (grade 3-5)
Gastrointestinal disorder NOS (serious)
Bleeding (grade 3-5)
Ulceration (grade 3-5)
Perforation stomach (grade 3-5)
Perforation of intestine (grade 3-5)
Sources:
0.35 % 2 times / day multiple, topical
Dose: 0.35 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.35 %, 2 times / day
Sources:
unhealthy
n = 135
Health Status: unhealthy
Condition: sprained ankle
Population Size: 135
Sources:
Other AEs: Gingival bleeding, Application site pruritus...
Other AEs:
Gingival bleeding (below serious, 1 patient)
Application site pruritus (below serious, 1 patient)
Inflammation (below serious, 1 patient)
Nasopharyngitis (below serious, 1 patient)
Ligament sprain (below serious, 1 patient)
Rash (below serious, 2 patients)
Drug eruption (below serious, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Vomiting Disc. AE
0.9 g single, oral
Overdose
Dose: 0.9 g
Route: oral
Route: single
Dose: 0.9 g
Sources: Page: p.152
unhealthy, 15
n = 1
Health Status: unhealthy
Condition: Knee pain
Age Group: 15
Sex: F
Population Size: 1
Sources: Page: p.152
Anorexia mild
Disc. AE
0.9 g single, oral
Overdose
Dose: 0.9 g
Route: oral
Route: single
Dose: 0.9 g
Sources: Page: p.152
unhealthy, 15
n = 1
Health Status: unhealthy
Condition: Knee pain
Age Group: 15
Sex: F
Population Size: 1
Sources: Page: p.152
Nausea mild
Disc. AE
0.9 g single, oral
Overdose
Dose: 0.9 g
Route: oral
Route: single
Dose: 0.9 g
Sources: Page: p.152
unhealthy, 15
n = 1
Health Status: unhealthy
Condition: Knee pain
Age Group: 15
Sex: F
Population Size: 1
Sources: Page: p.152
Headache below serious, 11 patient
20 mg 3 times / day multiple, oral
Dose: 20 mg, 3 times / day
Route: oral
Route: multiple
Dose: 20 mg, 3 times / day
Sources:
unhealthy, adult
n = 91
Health Status: unhealthy
Condition: Acute Postoperative Pain
Age Group: adult
Sex: M+F
Population Size: 91
Sources:
Pruritus below serious, 5 patients
20 mg 3 times / day multiple, oral
Dose: 20 mg, 3 times / day
Route: oral
Route: multiple
Dose: 20 mg, 3 times / day
Sources:
unhealthy, adult
n = 91
Health Status: unhealthy
Condition: Acute Postoperative Pain
Age Group: adult
Sex: M+F
Population Size: 91
Sources:
Vomiting below serious, 11 patient
20 mg 3 times / day multiple, oral
Dose: 20 mg, 3 times / day
Route: oral
Route: multiple
Dose: 20 mg, 3 times / day
Sources:
unhealthy, adult
n = 92
Health Status: unhealthy
Condition: Acute Postoperative Pain
Age Group: adult
Sex: M+F
Population Size: 92
Sources:
Nausea below serious, 34 patients
20 mg 3 times / day multiple, oral
Dose: 20 mg, 3 times / day
Route: oral
Route: multiple
Dose: 20 mg, 3 times / day
Sources:
unhealthy, adult
n = 92
Health Status: unhealthy
Condition: Acute Postoperative Pain
Age Group: adult
Sex: M+F
Population Size: 92
Sources:
Constipation below serious, 8 patients
20 mg 3 times / day multiple, oral
Dose: 20 mg, 3 times / day
Route: oral
Route: multiple
Dose: 20 mg, 3 times / day
Sources:
unhealthy, adult
n = 92
Health Status: unhealthy
Condition: Acute Postoperative Pain
Age Group: adult
Sex: M+F
Population Size: 92
Sources:
Pruritus below serious, 1 patient
40 mg 2 times / day multiple, oral
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, adult
n = 91
Health Status: unhealthy
Condition: Acute Postoperative Pain
Age Group: adult
Sex: M+F
Population Size: 91
Sources:
Headache below serious, 13 patients
40 mg 2 times / day multiple, oral
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, adult
n = 91
Health Status: unhealthy
Condition: Acute Postoperative Pain
Age Group: adult
Sex: M+F
Population Size: 91
Sources:
Presyncope below serious, 5 patients
40 mg 2 times / day multiple, oral
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, adult
n = 91
Health Status: unhealthy
Condition: Acute Postoperative Pain
Age Group: adult
Sex: M+F
Population Size: 91
Sources:
Deep vein thrombosis serious, 1 patient
40 mg 2 times / day multiple, oral
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, adult
n = 91
Health Status: unhealthy
Condition: Acute Postoperative Pain
Age Group: adult
Sex: M+F
Population Size: 91
Sources:
Vomiting below serious, 12 patients
40 mg 2 times / day multiple, oral
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, adult
n = 93
Health Status: unhealthy
Condition: Acute Postoperative Pain
Age Group: adult
Sex: M+F
Population Size: 93
Sources:
Nausea below serious, 36 patients
40 mg 2 times / day multiple, oral
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, adult
n = 93
Health Status: unhealthy
Condition: Acute Postoperative Pain
Age Group: adult
Sex: M+F
Population Size: 93
Sources:
Constipation below serious, 7 patients
40 mg 2 times / day multiple, oral
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, adult
n = 93
Health Status: unhealthy
Condition: Acute Postoperative Pain
Age Group: adult
Sex: M+F
Population Size: 93
Sources:
Post procedural haemorrhage below serious, 7 patients
40 mg 2 times / day multiple, oral
Dose: 40 mg, 2 times / day
Route: oral
Route: multiple
Dose: 40 mg, 2 times / day
Sources:
unhealthy, adult
n = 93
Health Status: unhealthy
Condition: Acute Postoperative Pain
Age Group: adult
Sex: M+F
Population Size: 93
Sources:
Headache below serious, 12 patients
40 mg 3 times / day multiple, oral
Dose: 40 mg, 3 times / day
Route: oral
Route: multiple
Dose: 40 mg, 3 times / day
Sources:
unhealthy, adult
n = 93
Health Status: unhealthy
Condition: Acute Postoperative Pain
Age Group: adult
Sex: M+F
Population Size: 93
Sources:
Pruritus below serious, 3 patients
40 mg 3 times / day multiple, oral
Dose: 40 mg, 3 times / day
Route: oral
Route: multiple
Dose: 40 mg, 3 times / day
Sources:
unhealthy, adult
n = 93
Health Status: unhealthy
Condition: Acute Postoperative Pain
Age Group: adult
Sex: M+F
Population Size: 93
Sources:
Headache below serious, 17 patients
40 mg 3 times / day multiple, oral
Dose: 40 mg, 3 times / day
Route: oral
Route: multiple
Dose: 40 mg, 3 times / day
Sources:
unhealthy, adult
n = 94
Health Status: unhealthy
Condition: Acute Postoperative Pain
Age Group: adult
Sex: M+F
Population Size: 94
Sources:
Vomiting below serious, 9 patients
40 mg 3 times / day multiple, oral
Dose: 40 mg, 3 times / day
Route: oral
Route: multiple
Dose: 40 mg, 3 times / day
Sources:
unhealthy, adult
n = 94
Health Status: unhealthy
Condition: Acute Postoperative Pain
Age Group: adult
Sex: M+F
Population Size: 94
Sources:
Bleeding grade 3-5
Disc. AE
50 mg 3 times / day multiple, oral
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Bursitis|Tendinitis|Gouty arthritis
Sources:
Myocardial infarction grade 3-5
Disc. AE
50 mg 3 times / day multiple, oral
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Bursitis|Tendinitis|Gouty arthritis
Sources:
Perforation of intestine grade 3-5
Disc. AE
50 mg 3 times / day multiple, oral
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Bursitis|Tendinitis|Gouty arthritis
Sources:
Perforation stomach grade 3-5
Disc. AE
50 mg 3 times / day multiple, oral
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Bursitis|Tendinitis|Gouty arthritis
Sources:
Stroke grade 3-5
Disc. AE
50 mg 3 times / day multiple, oral
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Bursitis|Tendinitis|Gouty arthritis
Sources:
Ulceration grade 3-5
Disc. AE
50 mg 3 times / day multiple, oral
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Bursitis|Tendinitis|Gouty arthritis
Sources:
Cardiac thrombosis serious
Disc. AE
50 mg 3 times / day multiple, oral
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Bursitis|Tendinitis|Gouty arthritis
Sources:
Gastrointestinal disorder NOS serious
Disc. AE
50 mg 3 times / day multiple, oral
Recommended
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Bursitis|Tendinitis|Gouty arthritis
Sources:
Application site pruritus below serious, 1 patient
0.35 % 2 times / day multiple, topical
Dose: 0.35 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.35 %, 2 times / day
Sources:
unhealthy
n = 135
Health Status: unhealthy
Condition: sprained ankle
Population Size: 135
Sources:
Drug eruption below serious, 1 patient
0.35 % 2 times / day multiple, topical
Dose: 0.35 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.35 %, 2 times / day
Sources:
unhealthy
n = 135
Health Status: unhealthy
Condition: sprained ankle
Population Size: 135
Sources:
Gingival bleeding below serious, 1 patient
0.35 % 2 times / day multiple, topical
Dose: 0.35 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.35 %, 2 times / day
Sources:
unhealthy
n = 135
Health Status: unhealthy
Condition: sprained ankle
Population Size: 135
Sources:
Inflammation below serious, 1 patient
0.35 % 2 times / day multiple, topical
Dose: 0.35 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.35 %, 2 times / day
Sources:
unhealthy
n = 135
Health Status: unhealthy
Condition: sprained ankle
Population Size: 135
Sources:
Ligament sprain below serious, 1 patient
0.35 % 2 times / day multiple, topical
Dose: 0.35 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.35 %, 2 times / day
Sources:
unhealthy
n = 135
Health Status: unhealthy
Condition: sprained ankle
Population Size: 135
Sources:
Nasopharyngitis below serious, 1 patient
0.35 % 2 times / day multiple, topical
Dose: 0.35 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.35 %, 2 times / day
Sources:
unhealthy
n = 135
Health Status: unhealthy
Condition: sprained ankle
Population Size: 135
Sources:
Rash below serious, 2 patients
0.35 % 2 times / day multiple, topical
Dose: 0.35 %, 2 times / day
Route: topical
Route: multiple
Dose: 0.35 %, 2 times / day
Sources:
unhealthy
n = 135
Health Status: unhealthy
Condition: sprained ankle
Population Size: 135
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Premature onset of labor, neonatal patent ductus arteriosus, and prostaglandin synthetase antagonists--a rat model of a human problem.
1979 Sep 15
Activation of apoptotic caspase-3 and nitric oxide synthase-2 in gastric mucosal injury induced by indomethacin.
1999 Feb
Seizures induced by NSAID.
1999 Jan
Prostaglandins and leukotriene B4 are potent inhibitors of 11beta-hydroxysteroid dehydrogenase type 2 activity in human choriocarcinoma JEG-3 cells.
1999 Jul
Indomethacin reduces the skin thermal damage in hyperthermic treatment of experimental malignant tumors.
1999 May-Jun
Capsaicin-sensitive afferent sensory nerves in modulating gastric mucosal defense against noxious agents.
1999 Nov
Tubulointerstitial nephritis with anti-neutrophil cytoplasmic antibody following indomethacin treatment.
1999 Nov
Indomethacin treatment decreases renal blood flow velocity in human neonates.
1999 Nov
Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus.
1999 Oct 2
Sulindac inhibits activation of the NF-kappaB pathway.
1999 Sep 17
Protective effect of lafutidine against indomethacin-induced intestinal ulceration in rats: relation to capsaicin-sensitive sensory neurons.
2000
Non-steroidal anti-inflammatory drugs with different cyclooxygenase inhibitory profiles that prevent aberrant crypt foci formation but vary in acute gastrotoxicity in a rat model.
2000 Dec
Neuropeptide Y enhances potassium excretion by mechanisms distinct from those controlling sodium excretion.
2000 Feb
Bartter syndrome in a neonate: early treatment with indomethacin.
2000 Feb
Induction of antitumor immunity by indomethacin.
2000 Feb
Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta.
2000 Feb 11
Indomethacin-induced apoptosis in esophageal adenocarcinoma cells involves upregulation of Bax and translocation of mitochondrial cytochrome C independent of COX-2 expression.
2000 Jul-Aug
Effect of indomethacin on IL-1beta, IL-6 and TNFalpha production by mononuclear cells of preterm newborns and adults.
2000 Mar
Effects of hydrogen peroxide scavenger Catalase on villous microcirculation in the rat small intestine in a model of inflammatory bowel disease.
2000 May
Indomethacin induces apoptosis and inhibits proliferation in chronic myeloid leukemia cells.
2000 May
Role of endothelin-converting enzyme-1 in the suppression of constitutive nitric oxide synthase in rat gastric mucosal injury by indomethacin.
2000 Nov
Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril.
2000 Nov
Inhibition of proteolysis by a cyclooxygenase inhibitor, indomethacin.
2000 Nov
A case of living-related kidney transplantation in Bartter's syndrome.
2000 Oct
Suppressed injury-induced rise in spinal prostaglandin E2 production and reduced early thermal hyperalgesia in iNOS-deficient mice.
2000 Sep 1
Effect of the nonsteroidal anti-inflammatory drug indomethacin on proliferation and apoptosis of colon carcinoma cells.
2001
Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations.
2001
Stimulation of cyclooxygenase-2-activity by nitric oxide-derived species in rat chondrocyte: lack of contribution to loss of cartilage anabolism.
2001 Apr 15
Indomethacin increases 15-PGDH mRNA expression in HL60 cells differentiated by PMA.
2001 Feb
Does exposure to magnesium sulfate in utero decrease the risk of necrotizing enterocolitis in premature infants?
2001 Feb
An investigation into the thermal behaviour of an amorphous drug using low frequency dielectric spectroscopy and modulated temperature differential scanning calorimetry.
2001 Jan
Agonist-specific regulation of monocyte chemoattractant protein-1 expression by cyclooxygenase metabolites in hepatic stellate cells.
2001 Mar
Effect of indomethacin on gallbladder inflammation and contractility during acute cholecystitis.
2001 Mar
Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery.
2001 Mar
Comparative effects of indomethacin on cell proliferation and cell cycle progression in tumor cells grown in vitro and in vivo.
2001 Mar 1
Inactivation of creatine kinase during the interaction of indomethacin with horseradish peroxidase and hydrogen peroxide: involvement of indomethacin radicals.
2001 Mar 14
Indomethacin prevents the induction of inducible nitric oxide synthase in murine peritoneal macrophages and decreases their nitric oxide production.
2001 Mar 9
Haloperidol-stomach lesions attenuation by pentadecapeptide BPC 157, omeprazole, bromocriptine, but not atropine, lansoprazole, pantoprazole, ranitidine, cimetidine and misoprostol in mice.
2001 Mar 9
Patents

Sample Use Guides

INDOCIN 75-150 mg daily in 3 or 4 divided doses.
Route of Administration: Oral
U251 cells were incubated for 24 h with different concentrations of indomethacin (0.03, 0.06, 0.13, 0.25, 0.5, 1 mkM), diclofenac (DIC),naproxen (NAP), or ketoprofen (KET), and the cell viability was assessed by MTT or crystal violet (CV) tests.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:24:48 GMT 2023
Edited
by admin
on Fri Dec 15 15:24:48 GMT 2023
Record UNII
0IMX38M2GG
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
INDOMETHACIN SODIUM
ORANGE BOOK   USAN   USP   VANDF  
USAN  
Official Name English
INDOMETHACIN SODIUM TRIHYDRATE
Common Name English
INDOMETACIN SODIUM HYDRATE [JAN]
Common Name English
INDOMETHACIN SODIUM [USAN]
Common Name English
SODIUM INDOMETHACIN TRIHYDRATE
Common Name English
INDOMETHACIN SODIUM [ORANGE BOOK]
Common Name English
INDOMETHACIN SODIUM [VANDF]
Common Name English
SODIUM 1-(P-CHLOROBENZOYL)-5-METHOXY-2-METHYLINDOLE-3-ACETATE, TRIHYDRATE
Systematic Name English
1H-INDOLE-3-ACETIC ACID, 1-(4-CHLOROBENZOYL)-5-METHOXY-2-METHYL-, SODIUM SALT, TRIHYDRATE
Common Name English
Indometacin sodium [WHO-DD]
Common Name English
Indometacin sodium trihydrate [WHO-DD]
Common Name English
INDOMETACIN SODIUM TRIHYDRATE
Common Name English
INDOMETACIN SODIUM [JAN]
Common Name English
INDOMETACIN SODIUM HYDRATE
Common Name English
INDOMETHACIN SODIUM SALT TRIHYDRATE [MI]
Common Name English
INDOMETACIN SODIUM [MART.]
Common Name English
INDOMETHACIN SODIUM SALT TRIHYDRATE
MI  
Common Name English
INDOMETHACIN SODIUM [USP MONOGRAPH]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1323
Created by admin on Fri Dec 15 15:24:48 GMT 2023 , Edited by admin on Fri Dec 15 15:24:48 GMT 2023
Code System Code Type Description
MERCK INDEX
m6279
Created by admin on Fri Dec 15 15:24:48 GMT 2023 , Edited by admin on Fri Dec 15 15:24:48 GMT 2023
PRIMARY Merck Index
SMS_ID
100000086425
Created by admin on Fri Dec 15 15:24:48 GMT 2023 , Edited by admin on Fri Dec 15 15:24:48 GMT 2023
PRIMARY
ChEMBL
CHEMBL6
Created by admin on Fri Dec 15 15:24:48 GMT 2023 , Edited by admin on Fri Dec 15 15:24:48 GMT 2023
PRIMARY
RXCUI
258329
Created by admin on Fri Dec 15 15:24:48 GMT 2023 , Edited by admin on Fri Dec 15 15:24:48 GMT 2023
PRIMARY
EPA CompTox
DTXSID00225256
Created by admin on Fri Dec 15 15:24:48 GMT 2023 , Edited by admin on Fri Dec 15 15:24:48 GMT 2023
PRIMARY
DRUG BANK
DBSALT001435
Created by admin on Fri Dec 15 15:24:48 GMT 2023 , Edited by admin on Fri Dec 15 15:24:48 GMT 2023
PRIMARY
CAS
74252-25-8
Created by admin on Fri Dec 15 15:24:48 GMT 2023 , Edited by admin on Fri Dec 15 15:24:48 GMT 2023
PRIMARY
WIKIPEDIA
Indomethacin sodium
Created by admin on Fri Dec 15 15:24:48 GMT 2023 , Edited by admin on Fri Dec 15 15:24:48 GMT 2023
PRIMARY
DAILYMED
0IMX38M2GG
Created by admin on Fri Dec 15 15:24:48 GMT 2023 , Edited by admin on Fri Dec 15 15:24:48 GMT 2023
PRIMARY
RXCUI
1294612
Created by admin on Fri Dec 15 15:24:48 GMT 2023 , Edited by admin on Fri Dec 15 15:24:48 GMT 2023
ALTERNATIVE
USAN
X-78
Created by admin on Fri Dec 15 15:24:48 GMT 2023 , Edited by admin on Fri Dec 15 15:24:48 GMT 2023
PRIMARY
PUBCHEM
23674731
Created by admin on Fri Dec 15 15:24:48 GMT 2023 , Edited by admin on Fri Dec 15 15:24:48 GMT 2023
PRIMARY
FDA UNII
0IMX38M2GG
Created by admin on Fri Dec 15 15:24:48 GMT 2023 , Edited by admin on Fri Dec 15 15:24:48 GMT 2023
PRIMARY
NCI_THESAURUS
C47999
Created by admin on Fri Dec 15 15:24:48 GMT 2023 , Edited by admin on Fri Dec 15 15:24:48 GMT 2023
PRIMARY
EVMPD
SUB02677MIG
Created by admin on Fri Dec 15 15:24:48 GMT 2023 , Edited by admin on Fri Dec 15 15:24:48 GMT 2023
PRIMARY
Related Record Type Details
ANHYDROUS->SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
The sum of the percentages of indomethacin related compound A and indomethacin related compound B is NMT 0.2%.
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
The sum of the percentages of indomethacin related compound A and indomethacin related compound B is NMT 0.2%.
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (GC)
USP
Related Record Type Details
ACTIVE MOIETY